istock-534325054_asiseeit

Steve Debenport / iStockphoto.com

1 November 2017Americas

The PTAB’s biggest test yet

The Patent Trial and Appeal Board (PTAB) is facing major scrutiny as big pharma companies look at ways to avoid inter partes reviews (IPRs) and the US Supreme Court looks into the very constitutionality of the procedure.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Attorney v examiner: Navigating patenting's AI tools ‘arms race’

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

USPTO clarifies AI's role in patent eligibility